REGENXBIO Inc. develops gene therapy candidates using its NAV® Technology Platform, focusing on treatments for rare and retinal diseases. The company is engaged in the research and development of adeno-associated virus (AAV) gene therapies, aiming to provide one-time treatments for patients with various diseases. REGENXBIO also has in-house capabilities for commercial-ready manufacturing.
